326.42MMarket Cap-7.89P/E (TTM)
3.770High3.570Low893.20KVolume3.690Open3.670Pre Close3.24MTurnover1.10%Turnover RatioLossP/E (Static)91.18MShares6.23052wk High-7.19P/B289.92MFloat Cap2.24052wk Low--Dividend TTM80.98MShs Float20.696Historical High--Div YieldTTM5.45%Amplitude0.618Historical Low3.623Avg Price1Lot Size
Aquestive Therapeutics Stock Forum
share your thoughts & ideas explain why 2025 will be amazing several break free and run
apextradez Wins so can you
Aquestive Therapeutics Receives U.S. FDA Orphan Drug Exclusivity for Libervant® (diazepam) Buccal Film in Pediatric Patients with Seizure Clusters Ages Two to Five
Thursday, 19th December at 8:00 am
WARREN, N.J., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery te...
1 min ago
Aquestive Therapeutics Announces Positive FDA Feedback and Reaffirms Nda Submission Guidance for Anaphylm™ (Epinephrine) Sublingual Film
Doesn't make sense to me?
Aquestive Therapeutics Announces Positive Topline Results from Oral Allergy Syndrome (OAS) Challenge Study for Anaphylm™ (epinephrine) Sublingual Film
Aquestive Therapeutics (NASDAQ: AQST) announced positive topline results from its Oral Allergy Syndrome (OAS) challenge study for Anaphylm™ sublingual film. The study met both primary and secondary endpoints, demonstrating rapid symptom resolution beginning two minutes after administration. The median time for...
Aquestive Therapeutics Inc - Oas Challenge Study Meets Primary and Secondary Endpoints
No comment yet